Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMZ905C)

• Drug Name: Mozavaptan Drug Info
• Synonyms: 137975-06-5; Opc-31260; Opc 31260; Mozavaptan [INN]; CHEMBL420762; OPC31260; 5-Dimethylamino-1-(4-(2-methylbenzoylamino)benzoyl)-2,3,4,5-tetrahydro-1H-benzazepine; N-(4-(5-(dimethylamino)-2,3,4,5-tetrahydro-1H-benzo[b]azepine-1-carbonyl)phenyl)-2-methylbenzamide; N-(4-((5-(Dimethylamino)-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl)phenyl)-2-methylbenzamide; N-(4-(((5RS)-5-(Dimethylamino)-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl)phenyl)-2-methylbenzamide; C27H29N3O2; OPC-31260

Indication

Disease Entry	ICD 11	Status	REF
Hyponatraemia	5C72	Approved	[1]

• Cross-matching ID:
  PubChem CID: 119369
  ChEBI ID: CHEBI:135694
  CAS Number: CAS 137975-06-5
  TTD Drug ID: DMZ905C

Molecule-Related Drug Atlas

Drug(s) Targeting Vasopressin V1 receptor (V1R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[7]
Lypressin	DM154EB	Amnesia	MB21.1	Approved	[8]
OPC-21268	DM7OVMH	Cardiac disease	BA00-BE2Z	Discontinued in Phase 2	[2]

Drug(s) Targeting Vasopressin V1b receptor (V1BR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Desmopressin	DMS3GVE	Diabetic complication	5A2Y	Approved	[9]
Oxytocin	DMDL27I	Autism spectrum disorder	6A02	Approved	[10]
ATOSIBAN	DMB7WYM	N. A.	N. A.	Phase 4	[11]
SSR149415	DMCMD93	Anxiety disorder	6B00-6B0Z	Phase 2	[12]
ABT-436	DMNAU1V	Anxiety disorder	6B00-6B0Z	Phase 2	[13]
ARGENINE VASOPRESSIN	DM8KN0Q	Discovery agent	N.A.	Investigative	[14]
D[Arg4,Orn8]VP	DM8D4QT	Discovery agent	N.A.	Investigative	[14]
D[Leu4,Lys8]VP	DMDBU7Q	Discovery agent	N.A.	Investigative	[14]
D[Arg4,Lys8]VP	DM69OVM	Discovery agent	N.A.	Investigative	[14]
D[Cha4,Lys8]VP	DM0GO7U	Discovery agent	N.A.	Investigative	[14]

Drug(s) Targeting Vasopressin V2 receptor (V2R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Desmopressin	DMS3GVE	Diabetic complication	5A2Y	Approved	[9]
Oxytocin	DMDL27I	Autism spectrum disorder	6A02	Approved	[15]
Tolvaptan	DMIWFRL	Autosomal dominant polycystic kidney disease	GB81	Approved	[16]
Conivaptan	DM1V329	Euvolemic hyponatremia	5C72	Approved	[17]
Vasopressin	DMQ2FPC	Diabetes insipidus	5A61.5	Approved	[18]
ATOSIBAN	DMB7WYM	N. A.	N. A.	Phase 4	[11]
Lixivaptan	DMDN4ZP	Hyponatraemia	5C72	Phase 3	[19]
Satavaptan	DME5PN3	Acute and chronic heart failure	BD1Z	Phase 3	[20]
SSR149415	DMCMD93	Anxiety disorder	6B00-6B0Z	Phase 2	[21]
ASP-7035	DMTF24A	Nocturia	MF55	Phase 2	[22]

Drug(s) Targeting Vasopressin V1a receptor (V1AR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Desmopressin	DMS3GVE	Diabetic complication	5A2Y	Approved	[9]
Oxytocin	DMDL27I	Autism spectrum disorder	6A02	Approved	[23]
Conivaptan	DM1V329	Euvolemic hyponatremia	5C72	Approved	[17]
Felypressin	DMHLP9C	Localisation	N.A.	Approved	[24]
Terlipressin	DMT9FH3	Hypertension	BA00-BA04	Approved	[25]
ATOSIBAN	DMB7WYM	N. A.	N. A.	Phase 4	[11]
Balovaptan	DMKMTDG	Autism spectrum disorder	6A02	Phase 3	[26]
PMX-53	DMZUAJ4	Atopic dermatitis	EA80	Phase 2	[27]
SSR149415	DMCMD93	Anxiety disorder	6B00-6B0Z	Phase 2	[21]
VA-111913	DMAYWXD	Dysmenorrhea	GA34.3	Phase 2	[28]

Drug(s) Affected By Cellular tumor antigen p53 (TP53)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cisplatin	DMRHGI9	Adenocarcinoma	2D40	Approved	[29]
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[30]
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[31]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[32]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[33]
Paclitaxel	DMLB81S	Breast carcinoma		Approved	[34]
Floxuridine	DM04LR2	Colorectal cancer	2B91.Z	Approved	[35]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[36]
Mechlorethamine	DM0CVXA	Chronic myelogenous leukaemia	2A20.0	Approved	[37]
Fulvestrant	DM0YZC6	Breast cancer	2C60-2C65	Approved	[38]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Vasopressin V1 receptor (V1R)	TTPFZJ1	NOUNIPROTAC	Antagonist	[2]
Vasopressin V1a receptor (V1AR)	TT4TFGN	V1AR_HUMAN	Inhibitor	[3]
Vasopressin V1b receptor (V1BR)	TTL9MHW	V1BR_HUMAN	Inhibitor	[4]
Vasopressin V2 receptor (V2R)	TTK8R02	V2R_HUMAN	Inhibitor	[5]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Cellular tumor antigen p53 (TP53)	OTIE1VH3	P53_HUMAN	Gene/Protein Processing	[6]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [2] Vasopressin (ADH). Nippon Rinsho. 1992 Dec;50(12):2893-900.
• [3] Nonpeptide vasopressin antagonists: a new group of hormone blockers entering the scene. Exp Clin Endocrinol Diabetes. 1999;107(3):157-65.
• [4] New analgesic drugs derived from phencyclidine. J Med Chem. 1981 May;24(5):496-9.
• [5] Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands. Prog Brain Res. 2002;139:197-210.
• [6] Identification of environmental chemicals that activate p53 signaling after in vitro metabolic activation. Arch Toxicol. 2022 Jul;96(7):1975-1987. doi: 10.1007/s00204-022-03291-5. Epub 2022 Apr 18.
• [7] Evidence in hyponatremia related to inappropriate secretion of ADH that V1 receptor stimulation contributes to the increase in renal uric acid clearance. J Am Soc Nephrol. 1996 May;7(5):805-10.
• [8] Human pain thresholds after the application of lypressin, a vasopressin analogue. Pharmacol Toxicol. 1987 Jul;61(1):16-9.
• [9] Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4. J Med Chem. 2004 Apr 22;47(9):2375-88.
• [10] The human V3 pituitary vasopressin receptor: ligand binding profile and density-dependent signaling pathways. Endocrinology. 1997 Oct;138(10):4109-22.
• [11] The discovery of GSK221149A: a potent and selective oxytocin antagonist. Bioorg Med Chem Lett. 2008 Jan 1;18(1):90-4.
• [12] Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92.
• [13] The vasopressin Avprlb receptor: Molecular and pharmacological studies. Stress. 2011 January; 14(1): 98-115.
• [14] Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasop... J Med Chem. 2007 Feb 22;50(4):835-47.
• [15] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 368).
• [16] Antibody-mediated disruption of the interaction between PCSK9 and the low-density lipoprotein receptor. Biochem J. 2009 May 1;419(3):577-84.
• [17] Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure. Circulation. 2001 Nov 13;104(20):2417-23.
• [18] Vasopressin receptors: structure/function relationships and signal transduction in target cells. J Soc Biol. 2005;199(4):351-9.
• [19] Emerging drugs for acute and chronic heart failure: current and future developments. Expert Opin Emerg Drugs. 2007 Mar;12(1):75-95.
• [20] Post-translational import of protein into the endoplasmic reticulum of a trypanosome: an in vitro system for discovery of anti-trypanosomal chemical entities. Biochem J. 2009 Apr 15;419(2):507-17.
• [21] Tetrahydroquinoline sulfonamides as vasopressin 1b receptor antagonists. Bioorg Med Chem Lett. 2009 Nov 1;19(21):6018-22.
• [22] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030285)
• [23] Mapping peptide-binding domains of the human V1a vasopressin receptor with a photoactivatable linear peptide antagonist. J Biol Chem. 1997 Oct 17;272(42):26536-44.
• [24] Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents. Prog Brain Res. 2008;170:473-512.
• [25] Investigational vasopressin receptor modulators in the pipeline. Expert Opin Investig Drugs. 2009 Aug;18(8):1119-31.
• [26] Discovery of Balovaptan, a Vasopressin 1a Receptor Antagonist for the Treatment of Autism Spectrum Disorder. J Med Chem. 2020 Feb 27;63(4):1511-1525.
• [27] Peptidomimetic C5a receptor antagonists with hydrophobic substitutions at the C-terminus: increased receptor specificity and in vivo activity. Bioorg Med Chem Lett. 2006 Oct 1;16(19):5088-92.
• [28] Clinical pipeline report, company report or official report of Avarx.
• [29] p53-R175H mutant gains new function in regulation of doxorubicin-induced apoptosis. Int J Cancer. 2005 Apr 10;114(3):331-6. doi: 10.1002/ijc.20818.
• [30] The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
• [31] Azidothymidine and cisplatin increase p14ARF expression in OVCAR-3 ovarian cancer cell line. Toxicol Appl Pharmacol. 2006 Oct 1;216(1):89-97. doi: 10.1016/j.taap.2006.04.015. Epub 2006 May 19.
• [32] Quantitative analysis of gene expression changes in response to genotoxic compounds. Toxicol In Vitro. 2017 Mar;39:15-28. doi: 10.1016/j.tiv.2016.11.004. Epub 2016 Nov 5.
• [33] Induction of apoptosis by cidofovir in human papillomavirus (HPV)-positive cells. Oncol Res. 2000;12(9-10):397-408. doi: 10.3727/096504001108747855.
• [34] Gallic acid potentiates the apoptotic effect of paclitaxel and carboplatin via overexpression of Bax and P53 on the MCF-7 human breast cancer cell line. J Biochem Mol Toxicol. 2021 Feb;35(2):e22638. doi: 10.1002/jbt.22638. Epub 2020 Oct 1.
• [35] Regulation of human dUTPase gene expression and p53-mediated transcriptional repression in response to oxaliplatin-induced DNA damage. Nucleic Acids Res. 2009 Jan;37(1):78-95. doi: 10.1093/nar/gkn910. Epub 2008 Nov 16.
• [36] Role of miRNA in the regulation of cannabidiol-mediated apoptosis in neuroblastoma cells. Oncotarget. 2019 Jan 1;10(1):45-59. doi: 10.18632/oncotarget.26534. eCollection 2019 Jan 1.
• [37] Nitrogen Mustard Alkylates and Cross-Links p53 in Human Keratinocytes. Chem Res Toxicol. 2022 Apr 18;35(4):636-650. doi: 10.1021/acs.chemrestox.1c00420. Epub 2022 Mar 21.
• [38] Fulvestrant induces resistance by modulating GPER and CDK6 expression: implication of methyltransferases, deacetylases and the hSWI/SNF chromatin remodelling complex. Br J Cancer. 2013 Nov 12;109(10):2751-62. doi: 10.1038/bjc.2013.583. Epub 2013 Oct 29.